First pan FGFR kinase inhibitor to be approved in the European Economic Area, for adults with unresectable or metastatic urothelial carcinoma and susceptible FGFR3 alterations Approval based on THOR results, showing 36 percent reduction in risk… Read More
PADCEV plus pembrolizumab approved based on EV-302 trial KIRKLAND, QC – Pfizer Canada ULC announced that Health Canada has approved PADCEV® (enfortumab vedotin) an antibody-drug conjugate (ADC) in combination with… Read More
Approval is based on the Phase 3 KEYNOTE-A39 trial KIRKLAND, QC – Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced that Health Canada has granted… Read More
DehydraTECH-liraglutide is outperforming DehydraTECH-semaglutide Select DehydraTECH-CBD formulations appear to continue to outperform DehydraTECH-semaglutide KELOWNA, BC – Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms… Read More
WELL Health subsidiary, OceanMD, and HEALWELL subsidiary, Intrahealth, announce a partnership to integrate OceanMD’s leading eReferral system across Intrahealth’s global network to enhance digital interoperability, streamline healthcare processes, and improve… Read More
